



## OvaScience to Present at Leerink Global Healthcare Conference

February 4, 2015

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 4, 2015-- OvaScience<sup>SM</sup> (NASDAQ: OVAS), a global life sciences company focused on the discovery, development and commercialization of new fertility treatments, announced today that Company management will present at the Leerink Global Healthcare Conference on Wednesday, February 11, 2015 at 1:25 pm ET at the Waldorf Astoria hotel in New York City.

A live audio webcast of the presentation can be accessed by visiting the Investors section of the Company's website at [www.ovascience.com](http://www.ovascience.com). A replay of the webcast will be archived on the OvaScience website for two weeks following the presentation.

### About OvaScience

OvaScience (NASDAQ: OVAS) is a global life sciences company dedicated to improving fertility for women around the world. OvaScience is discovering, developing and commercializing new fertility treatments because we believe women deserve more options. Each OvaScience treatment is based on the Company's proprietary technology platform that leverages the breakthrough discovery of egg precursor (EggPC<sup>SM</sup>) cells – immature egg cells found inside the protective ovarian lining. The AUGMENT<sup>SM</sup> treatment, a fertility option specifically designed to improve egg health, is available in certain IVF clinics in select international regions outside of the United States. OvaScience is developing the OvaPrime<sup>SM</sup> treatment, which could increase a woman's egg reserve, and the OvaTure<sup>SM</sup> treatment, a potential next-generation IVF treatment that could help a woman produce healthy, young, fertilizable eggs without hormone injections. For more information, please visit [www.ovascience.com](http://www.ovascience.com) and connect with us on [Twitter](#) and [Facebook](#).

### Forward-Looking Statements

*This press release includes forward-looking statements about the Company's plans for the AUGMENT treatment and its two fertility treatments in development. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: the possibility that international IVF clinics that we work with may determine not to begin or continue providing the AUGMENT treatment for commercial or other reasons; our expectation that the AUGMENT treatment and OvaPrime treatment meet the requirements of a class of products exempt from premarket review and approval under applicable regulations in those countries where we have launched or plan to introduce the AUGMENT treatment and plan to introduce the OvaPrime treatment; the science underlying our treatment and treatments in development (including the AUGMENT, OvaPrime and OvaTure treatments), which is unproven; our ability to obtain regulatory approval where necessary for our potential treatments; our ability to develop our potential treatments, including the OvaPrime and OvaTure treatments, on the timelines we expect, if at all; our ability to commercialize the AUGMENT treatment and our potential treatments, including the OvaPrime treatment, on the timelines we expect, if at all; as well as those risks more fully discussed in the "Risk Factors" section of our most recently filed Quarterly Report on Form 10-Q and/or Annual Report on Form 10-K. The forward-looking statements contained in this press release reflect our current views with respect to future events. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our view as of any date subsequent to the date hereof.*

###

Source: OvaScience

OvaScience  
Cara Petralia Mayfield, 617-714-9638  
Director, Corporate Communications  
[cmayfield@ovascience.com](mailto:cmayfield@ovascience.com)